NCT06026397View on ClinicalTrials.gov

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

February 11, 2024

Study Completion Date

February 11, 2024

Conditions
Chemotherapy-induced Diarrhea
Interventions
DRUG

SK10

Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

DRUG

Placebo

Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Trial Locations (1)

91206

Early Phase Clinical Unit (EPCU) - PAREXEL, Glendale

All Listed Sponsors
lead

Guangzhou Zhiyi Biotechnology Co., Ltd.

OTHER

NCT06026397 - A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter